Drugs / PLD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03387943 | Mar 2017 → Dec 2018 | poorly differentiated thyroid gland carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03387943 ↗ |
| Route | Intravenous | “intravenous infusion of liposomal doxorubicin 35 mg/m2” NCT03387943 ↗ |